462 results on '"Shah, Mithun V"'
Search Results
2. Clinical features and outcomes in primary nervous system histiocytic neoplasms
3. EASIX and CPSS Cytogenetics score-based composite risk model for patients with CMML undergoing allogeneic transplant
4. Somatic TP53 single nucleotide variants, indels and copy number alterations in chronic myelomonocytic leukemia (CMML)
5. Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
6. Neurological Manifestations of Histiocytic Disorders
7. Surrogates of Endothelial Injury Predict Survival After Post-transplant Cyclophosphamide
8. Long-term outcomes among adults with Langerhans cell histiocytosis
9. High EASIX score is an independent predictor of non-relapse mortality in patients with CMML undergoing allogeneic stem cell transplant
10. IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation
11. Relationship of iothalamate clearance and NRM in patients receiving fludarabine and melphalan reduced-intensity conditioning
12. Clinicopathologic correlates and prognostic impact of lymphoid aggregates in patients with myelodysplastic syndromes.
13. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
14. Factors Predicting Survival in Patients with TP53-Mutated Myeloid Neoplasms Following Allogeneic Stem Cell Transplant
15. Coronary Artery Calcium As a Predictor of Non-Relapse Mortality and Overall Survival in Patients Undergoing Post-Transplant Cyclophosphamide As Gvhd Prophylaxis
16. Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms
17. Impact of Wilms Tumor (WT1) Mutation on Relapse and Overall Survival in Acute Myeloid Leukemia Patients Following Allogenic Stem Cell Transplantation
18. Outcomes of HLA-DPB1 Mismatch in Patients Receiving Post-Transplant Cyclophosphamide for Graft Versus Host Disease Prophylaxis
19. Pilot Prospective Study of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Vexas Syndrome
20. Clinical and therapeutic implications of BRAF fusions in histiocytic disorders
21. Clinical features and outcomes of non-pulmonary unifocal adult Langerhans cell histiocytosis
22. IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation
23. Clinical characteristics, molecular aberrations, treatments, and outcomes of malignant histiocytosis.
24. Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS)
25. Isolated anemia in patients with large granular lymphocytic leukemia (LGLL)
26. BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis
27. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation
28. Pericardial Effusion as a Purported Manifestation of Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation
29. Allogeneic Hematopoietic Stem Cell Transplantation in the Outpatient Setting: The Mayo Clinic Experience
30. Risk of relapse in patients receiving azithromycin after allogeneic HSCT
31. A timeline of genetic variant enrichment: from multiple myeloma diagnosis to myeloma-associated myeloid malignancy
32. Reply
33. Baseline immune dysregulation in autologous stem cell transplant recipients is associated with a ‘graft versus host’-like syndrome and poor outcomes
34. Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
35. Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia
36. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
37. Prognostic impact and timing considerations for allogeneic hematopoietic stem cell transplantation in chronic myelomonocytic leukemia
38. The clinical and molecular spectrum ofETV6mutated myeloid neoplasms
39. A population-based study of chronic neutrophilic leukemia in the United States
40. Dedifferentiation of B-lymphoblastic leukemia/lymphoma with t(9;22) BCR::ABL1 to an undifferentiated neoplasm with strong keratin expression in a patient receiving blinatumomab
41. Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
42. Terminal Complement Inhibition in the Management of Transplant-Associated Thrombotic Microangiopathy: Single-Center Experience
43. Cpss Cytogenetics and Easix Score Based Composite Survival Model for Patients with CMML Undergoing Allogeneic Transplant
44. Efficacy of Donor Lymphocyte Infusions in Achieving Disease Control Among Myeloid Malignancy Patients Treated with an Allogeneic Hematopoietic Stem Cell Transplantation
45. Hematopoietic Stem Cell Transplant Outcome in STAG2-Mutated Myeloid Neoplasms
46. Surrogates of Endothelial Injury Predict Non-Relapse Mortality Among Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide-Based Gvhd Prophylaxis
47. BRAFV600Eis associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis
48. Ophthalmologic Involvement in Adults with Histiocytic Disorders
49. Seronegative Rheumatoid Arthritis and Innate Immune Activation is Frequent in Myeloid Neoplasms with Isocitrate Dehydrogenase 1/2 Mutations
50. Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.